They thus provide a rationale and a means for investigating therapeutic strategies, such as diet, metformin and/or glucagon-like peptide-1 (GLP-1) agonists, in combination with the targeting of autoimmunity, for preventing the progression to type 1 diabetes. This evidence concerns the gene GCG and Autoimmunity.